Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Current Investments: 2017-2024

Historic Cash & Current Investments for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $978.0 million.

  • Arcus Biosciences' Cash & Current Investments fell 23.69% to $831.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 2.49%. This contributed to the annual value of $978.0 million for FY2024, which is 28.85% up from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' Cash & Current Investments is $978.0 million, which was up 28.85% from $759.0 million recorded in FY2023.
  • Arcus Biosciences' Cash & Current Investments' 5-year high stood at $1.0 billion during FY2022, with a 5-year trough of $499.0 million in FY2021.
  • For the 3-year period, Arcus Biosciences' Cash & Current Investments averaged around $915.3 million, with its median value being $978.0 million (2024).
  • Per our database at Business Quant, Arcus Biosciences' Cash & Current Investments soared by 287.02% in 2020 and then slumped by 31.52% in 2021.
  • Over the past 5 years, Arcus Biosciences' Cash & Current Investments (Yearly) stood at $728.6 million in 2020, then tumbled by 31.52% to $499.0 million in 2021, then spiked by 102.20% to $1.0 billion in 2022, then fell by 24.78% to $759.0 million in 2023, then rose by 28.85% to $978.0 million in 2024.